Agreement signedPublished 3 Mar 2026

GlaxoSmithKline LLC /
RAPT Therapeutics, Inc.

GSK's unit completes takeover of RAPT Therapeutics

Buy side: GlaxoSmithKline LLC
Buy sideGlaxoSmithKline LLC
Target: RAPT Therapeutics, Inc.
TargetRAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. · 3 Mar 2026Source
Buy side: GlaxoSmithKline LLC
Buy sideGlaxoSmithKline LLC
Target: RAPT Therapeutics, Inc.
TargetRAPT Therapeutics, Inc.
01 / BuyerGlaxoSmithKline LLC
02 / TargetRAPT Therapeutics, Inc.
Source for the buyer and target: RAPT Therapeutics, Inc.

For the buyer and target.

“Agreement and Plan of Merger, dated as of January 19, 2026, by and among RAPT Therapeutics, Inc., GlaxoSmithKline LLC, Redrose Acquisition Co. and, solely for purposes of Section 8.11 thereto, GSK plc (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by RAPT Therapeutics, Inc. on January 20, 2026 (File No. 001-38997)).”

Published 3 Mar 2026

Open the source
01

What happened

GlaxoSmithKline LLC has finished its tender offer and merger for RAPT Therapeutics, Inc., which now operates as a direct wholly owned subsidiary of the buyer. The merger was carried out on March 3, 2026, under Section 251(h) of Delaware law, without a stockholder vote. [01]

Under the deal, RAPT shareholders were set to receive $58.00 per share in cash. RAPT's stock was delisted from Nasdaq, and its board was replaced with new directors and officers. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · RAPT Therapeutics, Inc.

GSK's unit completes takeover of RAPT Therapeutics

This document is the source for the companies, stage, figure and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Also stated

    “The merger was carried out on March 3, 2026, under Section 251(h) of Delaware law, without a stockholder vote”

    Open the source
  2. Published by RAPT Therapeutics, Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.